Core Viewpoint - Jinpai Home (603180.SH) reported its Q3 2025 results, highlighting a total institutional ownership of 70.12 million shares, accounting for 45.46% of the company's total equity, with a slight decrease of 1.00 percentage points from the previous quarter [1] Institutional Investors - Three institutional investors disclosed their holdings in Jinpai Home, including Xiamen Jianpan Group Co., Ltd., China Minsheng Bank Co., Ltd. - Everbright Baodexin Credit Enhancement Bond Fund, and Agricultural Bank of China Co., Ltd. - ICBC Credit Suisse Strategic Transformation Theme Equity Fund [1] - The total institutional ownership decreased by 1.00 percentage points compared to the last quarter [1] Public Funds - One public fund, Everbright Baodexin Credit Enhancement Bond Class A, reported a decrease in holdings compared to the previous quarter [1] - A total of 45 public funds that did not disclose their holdings this quarter include notable funds such as Huatai-PineBridge Advantage Selection Mixed Fund, China Merchants Zhongzheng Consumer Leader Index Enhanced A, and others [1] Social Security Funds - One social security fund, the National Social Security Fund 103 Portfolio, did not disclose its holdings this quarter [1]

Group 1 - The core viewpoint of the news is that Baicheng Pharmaceutical (301096.SZ) reported its semi-annual results for 2025, revealing significant institutional investor activity and changes in shareholding [1] - As of August 27, 2025, a total of 10 institutional investors disclosed holdings in Baicheng Pharmaceutical A-shares, with a combined holding of 14.74 million shares, accounting for 13.50% of the total share capital [1] - The top ten institutional investors include various management partnerships and funds, with their combined holding percentage decreasing by 1.07 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, Rongtong Health Industry Flexible Allocation Mixed A/B, reported a slight decrease in holdings compared to the previous quarter [2] - Two new public funds were disclosed during this period, namely Caitong Technology Innovation Mixed A and Caitong Fusheng Mixed Initiation (LOF) A [2] - Two public funds, including Everbright Baodexin Credit Enhancement Bond Class A and Everbright Baodexin Anqi Bond Class A, were not disclosed in this period compared to the previous quarter [2]

Group 1 - The core viewpoint of the news is that Jianfan Bio (300529.SZ) reported a decrease in institutional investor holdings in its A-shares, with a total of 51.87 million shares held by six institutions, representing 6.49% of the total share capital, down by 2.00 percentage points from the previous quarter [1] Group 2 - In the public fund sector, two public funds increased their holdings, including Huabao Zhongzheng Medical ETF and Southern Zhongzheng 500 ETF, with an increase ratio of 0.25% [2] - Two public funds decreased their holdings, namely, Zhaoshang Guozhen Biomedical Index A and Yifangda Growth Enterprise ETF, with a decrease ratio of 0.11% [2] - Six public funds did not disclose their holdings in the current period, including Guangda Baodexin Credit Enhancement Bond A and others [2] Group 3 - Regarding foreign investment, the Hong Kong Central Clearing Limited is noted as an institution that did not disclose its holdings in the current period [3]